Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone XR in mild to moderate Alzheimer's disease
2005-005089-34Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Rosiglitazone XR with Placebo (2 arms). Primary endpoint: Change in cerebral glucose metabolism. Started Jun 2007; status: completed.
02
Drugs
rosiglitazone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2005-005089-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005089-34.